<DOC>
	<DOCNO>NCT00508222</DOCNO>
	<brief_summary>The study design test hypothesis patient co-infected HIV HCV exhibit maximal virologic suppression double class antiretroviral ( ARV ) regimen , include two Nucleoside Reverse Transcriptase Inhibitors ( NRTIs ) Non-nucleoside Reverse Transcriptase Inhibitors ( NNRTI ) Protease Inhibitor ( PI ) ( boost ritonavir ) , simplification highly active antiretroviral therapy ( HAART ) Kaletra® monotherapy represent viable strategy without negative impact virologic control HIV infection .</brief_summary>
	<brief_title>Kaletra Monotherapy HIV/HCV Co-infected Subjects</brief_title>
	<detailed_description>The primary purpose study determine safe effective drug Kaletra® treat HIV administer without antiretroviral drug ( monotherapy ) . Kaletra® 2 protease inhibitor ( lopinavir ritonavir ) combine one dosage form . Kaletra monotherapy experimental subject eligible study switch successful conventional triple therapy unproven experimental therapy . Approximately 40 HIV/HCV coinfected participant , age 18 year participate study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Inclusion Criteria 1 . Subject confirm willingness participate study inform aspect trial relevant decision participate , sign date IRB / IEC approve informed consent form . 2 . Subject HIV positive HCV positive ( must viremic HCV , antibody positive ) . 3 . Subject 18 year age old . 4 . Subject must undetectable viral load ( VL ) less 50 copies/ml last 6 month HAART therapy . 5 . Subject must take medication could interact Kaletra® enhance hepatic toxicity . 6 . Subject 's serum AST ALT level must &amp; lt ; 5 time normal ( grade 2 less ) start study . 7 . Subject must harbour viral strain resistant Kaletra® start study . 8 . Subject Karnofsky Score 70 great . 9 . If female , subject must negative pregnancy test agree use , duration study , barrier method birth control history prove reliability judge investigator . 10 . Subject require agrees take , duration study , medication contraindicate Kaletra® ( list protocol ) . Exclusion Criteria 1 . Subject active hepatitis B ( HbsAg + ) . 2 . Subject history substance abuse psychiatric illness could preclude compliance protocol . 3 . Subject follow abnormal laboratory test result screen : Hemoglobin 8.0 g/dL Absolute neutrophil count 500 cells/mL Platelet count 20,000/mL ALT AST 5x Upper Limit Normal ( ULN ) Creatinine 1.5 x ULN 4 . Female subject pregnant lactating . 5 . Subject receive investigational drug within 30 day prior initiation study dose . 6 . Subject exhibit viral strain resistant lopinavir . 7 . Subject receive systemic chemotherapy . 8 . The subject , opinion principal investigator , unlikely comply study protocol unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>HCV</keyword>
	<keyword>HIV/HCV Co-infection</keyword>
	<keyword>Kaletra Monotherapy</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>